drugset / Trial / NCT05164731

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above

NCT05164731 ↗

Non-randomizedSingle-groupOpen-labelPrevention

Summary

To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 3, 4, 5, or 6 months since finished two doses schedule of Institute of Medical Biology Chinese Academy of Medical Sciences SARS-CoV-2 inactivated vaccine.

Timeline

Start
2021-12-16
Primary completion
2022-08-30
Completion
2022-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SARS-CoV-2 Vaccine, Inactivated (Vero Cell) Vaccine — —

Indications